Genesis R&D Inks Deal to Sell 7.4M Shares of Stock

The private placement, the New Zealand-based company said, is expected to close within the next two weeks.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.